363 related articles for article (PubMed ID: 15691646)
1. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer.
Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ
Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346
[TBL] [Abstract][Full Text] [Related]
3. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck.
Fouret P; Temam S; Charlotte F; Lacau-St-Guily J
Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767
[TBL] [Abstract][Full Text] [Related]
4. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma--a prospective study.
Ma BB; Poon TC; To KF; Zee B; Mo FK; Chan CM; Ho S; Teo PM; Johnson PJ; Chan AT
Head Neck; 2003 Oct; 25(10):864-72. PubMed ID: 12966511
[TBL] [Abstract][Full Text] [Related]
6. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.
Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G
Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy.
Chua DT; Nicholls JM; Sham JS; Au GK
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):11-20. PubMed ID: 15093894
[TBL] [Abstract][Full Text] [Related]
8. Cyclin A as a predictive factor for chemotherapy response in advanced head and neck cancer.
Rodriguez-Pinilla M; Rodriguez-Peralto JL; Hitt R; Sanchez JJ; Ballestin C; Diez A; Sanchez-Verde L; Alameda F; Sanchez-Cespedes M
Clin Cancer Res; 2004 Dec; 10(24):8486-92. PubMed ID: 15623629
[TBL] [Abstract][Full Text] [Related]
9. A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.
Etienne MC; Pivot X; Formento JL; Bensadoun RJ; Formento P; Dassonville O; Francoual M; Poissonnet G; Fontana X; Schneider M; Demard F; Milano G
Br J Cancer; 1999 Apr; 79(11-12):1864-9. PubMed ID: 10206306
[TBL] [Abstract][Full Text] [Related]
10. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy.
Gasparini G; Bevilacqua P; Bonoldi E; Testolin A; Galassi A; Verderio P; Boracchi P; Guglielmi RB; Pezzella F
Clin Cancer Res; 1995 Nov; 1(11):1375-83. PubMed ID: 9815934
[TBL] [Abstract][Full Text] [Related]
11. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.
Ang KK; Berkey BA; Tu X; Zhang HZ; Katz R; Hammond EH; Fu KK; Milas L
Cancer Res; 2002 Dec; 62(24):7350-6. PubMed ID: 12499279
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.
Bentzen SM; Atasoy BM; Daley FM; Dische S; Richman PI; Saunders MI; Trott KR; Wilson GD
J Clin Oncol; 2005 Aug; 23(24):5560-7. PubMed ID: 16110017
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
Buchholz TA; Tu X; Ang KK; Esteva FJ; Kuerer HM; Pusztai L; Cristofanilli M; Singletary SE; Hortobagyi GN; Sahin AA
Cancer; 2005 Aug; 104(4):676-81. PubMed ID: 15981280
[TBL] [Abstract][Full Text] [Related]
14. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
Argiris A; Li Y; Forastiere A
Cancer; 2004 Nov; 101(10):2222-9. PubMed ID: 15452834
[TBL] [Abstract][Full Text] [Related]
16. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of pharmacokinetic modulating chemotherapy combined with cisplatin as induction chemotherapy in resectable locally advanced head and neck cancer: phase II study.
Chang PM; Chen PM; Chu PY; Wang LW; Tai SK; Tsai TL; Huang JL; Wang YF; Chang SY; Yang MH
Cancer Chemother Pharmacol; 2008 Dec; 63(1):9-17. PubMed ID: 18343925
[TBL] [Abstract][Full Text] [Related]
18. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.
Handra-Luca A; Hernandez J; Mountzios G; Taranchon E; Lacau-St-Guily J; Soria JC; Fouret P
Clin Cancer Res; 2007 Jul; 13(13):3855-9. PubMed ID: 17606717
[TBL] [Abstract][Full Text] [Related]
19. Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer.
Sauter ER; Ridge JA; Litwin S; Langer CJ
Clin Cancer Res; 1995 Nov; 1(11):1407-12. PubMed ID: 9815938
[TBL] [Abstract][Full Text] [Related]
20. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
